423 related articles for article (PubMed ID: 26951312)
1. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
Halabi S; Kelly WK; Ma H; Zhou H; Solomon NC; Fizazi K; Tangen CM; Rosenthal M; Petrylak DP; Hussain M; Vogelzang NJ; Thompson IM; Chi KN; de Bono J; Armstrong AJ; Eisenberger MA; Fandi A; Li S; Araujo JC; Logothetis CJ; Quinn DI; Morris MJ; Higano CS; Tannock IF; Small EJ
J Clin Oncol; 2016 May; 34(14):1652-9. PubMed ID: 26951312
[TBL] [Abstract][Full Text] [Related]
2. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
[TBL] [Abstract][Full Text] [Related]
3. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
[TBL] [Abstract][Full Text] [Related]
4. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
5. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
Halabi S; Dutta S; Tangen CM; Rosenthal M; Petrylak DP; Thompson IM; Chi KN; Araujo JC; Logothetis C; Quinn DI; Fizazi K; Morris MJ; Eisenberger MA; George DJ; De Bono JS; Higano CS; Tannock IF; Small EJ; Kelly WK
J Clin Oncol; 2019 Feb; 37(5):403-410. PubMed ID: 30576268
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
7. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
8. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
9. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
10. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
11. Visceral disease in castration-resistant prostate cancer.
Pezaro C; Omlin A; Lorente D; Rodrigues DN; Ferraldeschi R; Bianchini D; Mukherji D; Riisnaes R; Altavilla A; Crespo M; Tunariu N; de Bono J; Attard G
Eur Urol; 2014 Feb; 65(2):270-273. PubMed ID: 24295792
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
Loriot Y; Fizazi K; de Bono JS; Forer D; Hirmand M; Scher HI
Cancer; 2017 Jan; 123(2):253-262. PubMed ID: 27648814
[TBL] [Abstract][Full Text] [Related]
13. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
[TBL] [Abstract][Full Text] [Related]
14. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
Armstrong AJ; Al-Adhami M; Lin P; Parli T; Sugg J; Steinberg J; Tombal B; Sternberg CN; de Bono J; Scher HI; Beer TM
JAMA Oncol; 2020 Feb; 6(2):217-225. PubMed ID: 31830211
[TBL] [Abstract][Full Text] [Related]
15. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
Goodman OB; Flaig TW; Molina A; Mulders PF; Fizazi K; Suttmann H; Li J; Kheoh T; de Bono JS; Scher HI
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):34-9. PubMed ID: 24080993
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
17. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
Doctor SM; Tsao CK; Godbold JH; Galsky MD; Oh WK
Cancer; 2014 Mar; 120(6):833-9. PubMed ID: 25302607
[TBL] [Abstract][Full Text] [Related]
18. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
19. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Alumkal JJ; Chowdhury S; Loriot Y; Sternberg CN; de Bono JS; Tombal B; Carles J; Flaig TW; Dorff TB; Phung D; Forer D; Noonberg SB; Mansbach H; Beer TM; Higano CS
Clin Genitourin Cancer; 2017 Oct; 15(5):610-617.e3. PubMed ID: 28344102
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
Chowdhury S; Bjartell A; Lumen N; Maroto P; Paiss T; Gomez-Veiga F; Birtle A; Kramer G; Kalinka E; Spaëth D; Feyerabend S; Matveev V; Lefresne F; Lukac M; Wapenaar R; Costa L
Target Oncol; 2020 Jun; 15(3):301-315. PubMed ID: 32500294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]